New FDA Draft Guidance Regarding Financial Disclosures by Clinical Investigators
Monday, July 11, 2011

New recommendations recently released by the FDA demonstrate the changing environment for conflicts of interest management and emphasize the need for pharmaceutical companies, medical device manufacturers and health care providers to ensure they have internal processes that adequately anticipate and meet the baseline requirements.

 

Please click here to view the entire White Paper in Adobe PDF format.
(Adobe Acrobat Reader required, available for free download here)

 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins